Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
AstraZeneca
Daiichi Sankyo
Teva
Julphar
Fish and Richardson
Cantor Fitzgerald
Baxter

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,141,237

« Back to Dashboard

Which drugs does patent 7,141,237 protect, and when does it expire?

Patent 7,141,237 protects EVOCLIN and is included in one NDA.

This patent has thirty patent family members in fifteen countries.
Summary for Patent: 7,141,237
Title:Pharmaceutical foam
Abstract:The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
Inventor(s): Abram; Albert Zorko (Wantirna, AU), Hunt; Barry Thomas (Carnegie, AU)
Assignee: Connetics Australia Pty Ltd. (Rowville, AU)
Application Number:10/763,379
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Use; Formulation;

Drugs Protected by US Patent 7,141,237

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mylan Pharms Inc EVOCLIN clindamycin phosphate AEROSOL, FOAM;TOPICAL 050801-001 Oct 22, 2004 AT RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,141,237

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,586,008 Pharmaceutical foam ➤ Sign Up
9,486,394 Pharmaceutical foam ➤ Sign Up
7,374,747 Pharmaceutical foam ➤ Sign Up
7,749,488 Pharmaceutical foam ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Julphar
Queensland Health
Argus Health
Cerilliant
Teva
US Army
Chinese Patent Office
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.